Literature DB >> 7890396

Protective immunity induced by Bacillus anthracis toxin-deficient strains.

C Pezard1, M Weber, J C Sirard, P Berche, M Mock.   

Abstract

The two toxins secreted by Bacillus anthracis are composed of binary combinations of three proteins: protective antigen (PA), lethal factor (LF), and edema factor (EF). Six mutant strains that are deficient in the production of one or two of these toxin components have been previously constructed and characterized (C. Pezard, E. Duflot, and M. Mock, J. Gen. Microbiol. 139:2459-2463, 1993). In this work, we examined the antibody response to the in vivo production of PA, LF, and EF in mice immunized with spores of strains producing these proteins. High titers of antibody to PA were observed after immunization with all strains producing PA, while titers of antibodies to EF and LF were weak in animals immunized with strains producing only EF or LF. In contrast, immunization with strains producing either PA and EF or PA and LF resulted in an increased antibody response to EF or LF, respectively. The differing levels of protection from a lethal anthrax challenge afforded to mice immunized with spores of the mutant strains not only confirm the role of PA as the major protective antigen in the humoral response but also indicate a significant contribution of LF and EF to immunoprotection. We observed, however, that PA-deficient strains were also able to provide some protection, thereby suggesting that immune mechanisms other than the humoral response may be involved in immunity to anthrax. Finally, a control strain lacking the toxin-encoding plasmid was unable to provide protection or elicit an antibody response against bacterial antigens, indicating a possible role for pXO1 in the survival of B. anthracis in a host.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890396      PMCID: PMC173160          DOI: 10.1128/iai.63.4.1369-1372.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Purification of factor I and recognition of a third factor of the anthrax toxin.

Authors:  J L STANLEY; H SMITH
Journal:  J Gen Microbiol       Date:  1961-09

2.  Immunization studies with attenuated strains of Bacillus anthracis.

Authors:  B E Ivins; J W Ezzell; J Jemski; K W Hedlund; J D Ristroph; S H Leppla
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

3.  Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig.

Authors:  S F Little; G B Knudson
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

4.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

5.  Immunologic studies of anthrax. IV. Evaluation of the immunogenicity of three components of anthrax toxin.

Authors:  B G Mahlandt; F Klein; R E Lincoln; B W Haines; W I Jones; R H Friedman
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

6.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

Review 7.  Anthrax: the disease in relation to vaccines.

Authors:  P Hambleton; J A Carman; J Melling
Journal:  Vaccine       Date:  1984-06       Impact factor: 3.641

8.  Demonstration of a capsule plasmid in Bacillus anthracis.

Authors:  B D Green; L Battisti; T M Koehler; C B Thorne; B E Ivins
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

9.  Evidence for plasmid-mediated toxin production in Bacillus anthracis.

Authors:  P Mikesell; B E Ivins; J D Ristroph; T M Dreier
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

10.  Effects of anthrax toxin components on human neutrophils.

Authors:  J O'Brien; A Friedlander; T Dreier; J Ezzell; S Leppla
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

View more
  52 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation.

Authors:  Indira T Kudva; Robert W Griffin; Jeonifer M Garren; Stephen B Calderwood; Manohar John
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

4.  Bacillus anthracis sortase A (SrtA) anchors LPXTG motif-containing surface proteins to the cell wall envelope.

Authors:  Andrew H Gaspar; Luciano A Marraffini; Elizabeth M Glass; Kristin L Debord; Hung Ton-That; Olaf Schneewind
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

5.  Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Authors:  Orit Gat; Haim Grosfeld; Naomi Ariel; Itzhak Inbar; Galia Zaide; Yehoshua Broder; Anat Zvi; Theodor Chitlaru; Zeev Altboum; Dana Stein; Sara Cohen; Avigdor Shafferman
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Cell surface-exposed tetanus toxin fragment C produced by recombinant Bacillus anthracis protects against tetanus toxin.

Authors:  S Mesnage; M Weber-Levy; M Haustant; M Mock; A Fouet
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

8.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

9.  A mathematical simulation of the inflammatory response to anthrax infection.

Authors:  Rukmini Kumar; Carson C Chow; John D Bartels; Gilles Clermont; Yoram Vodovotz
Journal:  Shock       Date:  2008-01       Impact factor: 3.454

10.  Suppression of dendritic cell activation by anthrax lethal toxin and edema toxin depends on multiple factors including cell source, stimulus used, and function tested.

Authors:  Ping-Jen Joe Chou; Catherine A Newton; Izabella Perkins; Herman Friedman; Thomas W Klein
Journal:  DNA Cell Biol       Date:  2008-12       Impact factor: 3.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.